# Hybrid Sirolimus-eluting Versus Everolimus-eluting Stents for Total Coronary Occlusions

> **NCT01516723** · PHASE3 · UNKNOWN · sponsor: **R&D Cardiologie** · enrollment: 330 (estimated)

## Conditions studied

- Coronary Artery Disease
- Coronary Disease
- Coronary Stenosis

## Interventions

- **DEVICE:** Hybrid sirolimus- and everolimus-eluting stents (ORSIRO, XIENCE PRIME)

## Key facts

- **NCT ID:** NCT01516723
- **Lead sponsor:** R&D Cardiologie
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-02
- **Primary completion:** 2016-02
- **Final completion:** 2020-05
- **Target enrollment:** 330 (ESTIMATED)
- **Last updated:** 2017-03-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01516723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01516723, "Hybrid Sirolimus-eluting Versus Everolimus-eluting Stents for Total Coronary Occlusions". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01516723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*